LENZ Therapeutics, Inc. (LENZ)

NASDAQ: LENZ · USD

$3.19

+0.03 (+1.1%)· Recorded snapshot

Market cap	100.1M
Revenue (ttm)	21.5M
Net income (ttm)	-126M
EPS (ttm)	-$4.12
Shares out	31.4M
Volume	475,203
Beta	1.73

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 21.5M
Net income (ttm): -126M
EPS (ttm): -$4.12
Market cap: 100.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-59.2

P25 n/aP50 n/aP75 n/a

ROIC-39.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All LENZ indicators

Market & fundamental data

Available fields

191

Groups with data

Currency

USD

Showing 191 of 191 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001815776
Company name	LENZ Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	52635N103
Earnings date	2026-10-29
Earnings time	bmo
Employees	152
Employees change	110
Employees growth	261.9%
Enterprise value	$-119.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2019
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2021-06-25
Is primary listing	Yes
Is SPAC	No
ISIN number	US52635N1037
Last 10-K release date	2026-03-24
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$100.1M
Market cap category	Micro-Cap
Next earnings date	2026-10-29
Options	Yes
Price	$3.19
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	LENZ
U.S. state	California
Website	https://www.lenz-tx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-129.31%
FCF / EV yield	94.44%
FCF yield	-116.42%
Forward P/S	4.55x
P/B ratio	0.45x
P/S ratio	4.58x
Price / tangible book value	0.45x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	91.74%
Operating margin	-631.7%
Pretax margin	-586.71%
Profit per employee	$-828,961
Revenue per employee	$141,283
ROA	-37.36%
ROCE	-61.84%
ROE	-59.21%
ROIC	-39.69%
SBC / revenue	74.22%
Tax / revenue	0.02%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Gross profit growth	294.02%
Gross profit growth (Q)	4.12%
Gross profit growth 3Y	9.51%
Net income growth years	0
Revenue growth	329.5%
Revenue growth (Q)	9.72%
Revenue growth (QoQ)	188.58%
Revenue growth 3Y	12.71%
Revenue growth quarters	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-511,000
Depreciation and amortization	$453,000
EBIT	$-135.7M
EBITDA	$-135.2M
EPS	$-4.12
FCF per share	$-3.64
Financing cash flow	$123.6M
Free cash flow	$-114.4M
Free cash flow minus SBC	$-130.4M
Gross profit	$19.7M
Income taxes	$5,000
Investing cash flow	$-23.2M
Net cash flow	$-13.5M
Net income	$-126M
Operating cash flow minus SBC	$-129.8M
Operating income	$-135.7M
Revenue	$21.5M
Stock-based compensation	$15.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	20.12
Book value per share	$6.98
Debt / equity	0
Long-term assets	$3.3M
Long-term liabilities	$122,000
Net cash (debt)	$219.4M
Net cash / market cap	223.27%
Net cash growth	5.26%
Net debt / equity	-1
Piotroski F-Score	2
Property, plant and equipment	$1.5M
Shareholders' equity	$219.3M
Tangible book value	$219.3M
Tangible book value per share	$6.98
Total assets	$236.6M
Total cash	$220M
Total debt	$569,000
Total liabilities	$17.3M
WACC	13.68%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.09
Current assets	$233.3M
Current liabilities	$17.2M
Current ratio	13.55
Net working capital	$-3.5M
Quick ratio	12.91
Working capital	$216.1M
Working capital turnover	0.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-10.84%
Dividend per share	$0.00
Dividend yield	0%
Last dividend	$1.03
Shareholder yield	-10.84%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$6.14
1D price change	1.11%
1M price change	-18.65%
1M total return	-18.65%
1W price change	-1.09%
1W total return	-1.09%
1Y price change	-89.82%
1Y return CAGR	-89.84%
1Y total return	-89.82%
20-day SMA	$3.42
200-day SMA	$8.16
3M price change	-44.12%
3M total return	-44.12%
50-day SMA	$4.13
50-day SMA vs 200-day SMA	50under200
52-week high	$32.13
52-week high date	2025-11-24
52-week low	$3.06
52-week low date	2026-10-23
6M price change	-67.37%
6M total return	-67.37%
All-time high	$50.40
All-time high date	2025-10-02
All-time low	$3.06
All-time low date	2026-10-23
Average true range (ATR)	$0.21
Average volume	713.4K
Beta (1Y)	2.22
Beta (2Y)	1.77
Beta (5Y)	1.73
Change from 52-week high	-90.09%
Change from 52-week low	4.09%
Change from all-time high	-93.68%
Change from all-time low	4.08%
Change from open	2.74%
Day's gap	-1.59%
Dollar volume	$1.5M
High price	$3.22
Low price	$3.07
Monthly RSI	33.86
Open price	$3.10
Position in 52-week range	79.31%
Premarket change	1.59%
Premarket close	$3.15
Premarket price	$3.20
Premarket volume	827
Previous close	$3.15
Price vs 150-day SMA	-48.16%
Price vs 20-day SMA	-6.9%
Price vs 200-day SMA	-60.98%
Price vs 50-day SMA	-22.86%
Relative volume	0.67
Return from IPO price	-81.6%
RSI	33.66
Sharpe ratio	-2.51
Sortino ratio	-2.95
Volume	475.2K
Weekly RSI	29.57
YTD price change	-80.09%
YTD total return	-80.09%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	18.4M
Float percentage	58.54%
Shares change (QoQ)	0.07%
Shares change (YoY)	10.84%
Shares held by insiders	2.65%
Shares held by institutions	66.29%
Shares outstanding	31.4M
Short % of float	57.42%
Short % of shares	33.61%
Short ratio	14 days

Deeper analysis on LENZ

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this LENZ report

Is a complete LENZ research report available?

No complete published report is available for LENZ Therapeutics, Inc. (LENZ) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

LENZ Therapeutics, Inc. (LENZ)

Price

Financial snapshot

Fair-value bridge

Latest news · LENZ

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All LENZ indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on LENZ

Frequently asked questions